Targeted and immune-based therapies for hepatocellular carcinoma
返回论文页
|更新时间:2023-12-22
|
Targeted and immune-based therapies for hepatocellular carcinoma
Journal of Chongqing Medical UniversityVol. 44, Issue 12, Pages: 1547(2019)
作者机构:
重庆大学附属肿瘤医院内分泌肾病内科,重庆,400030
作者简介:
基金信息:
DOI:
CLC:
Published:2019,
扫 描 看 全 文
Hu Mingyang, Wu Qinan, Wu Yongzhong. Targeted and immune-based therapies for hepatocellular carcinoma. [J]. Journal of Chongqing Medical University 44(12):1547(2019)
DOI:
Hu Mingyang, Wu Qinan, Wu Yongzhong. Targeted and immune-based therapies for hepatocellular carcinoma. [J]. Journal of Chongqing Medical University 44(12):1547(2019)DOI:
Targeted and immune-based therapies for hepatocellular carcinoma
Hepatocellular carcinoma(HCC) has become one of the most common and deadly malignancies. In recent years,the third phase of drugs based on target and immunity has obtained better results,more drugs focusing on specific tumor metabolic pathways and immune checkpoints are under clinical development,and some drugs have been identified that can improve the prognosis of liver cancer patients. Treatments of HCC changes rapidly. This article reviewed the mechanism,side effects,efficacy and ongoing research of targeted therapy and immunotherapy drugs for HCC.